Helix BioPharma names CEO Thomas Mehrling to board, Janusz Grabski resigns
Reuters2026/08/14 21:01- Helix BioPharma announced board changes effective immediately.
- Janusz Grabski resigned as a director.
- CEO Thomas Mehrling, M.D., Ph.D., was appointed to the board under a nomination right tied to the 2025 Laevoroc acquisition.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Delta Electronics (Thailand)'s Recent Selloff Presents Accumulation Opportunity -- Market Talk
The data center construction boom may increase inflationary pressure, and the Reserve Bank of Australia may be forced to maintain high interest rates.
The data center construction boom in Australia may lead to demand exceeding the supply capacity of the economy, which could push up inflation and force the Reserve Bank of Australia to maintain higher interest rates.
Reliance step-down unit Roptonal dissolves in Cyprus with effect Aug. 18, 2026
Crypto prices
More
